Electrochemiluminescence method improves sST2 detection sensitivity in heart failure, indicating a potential for early diagnosis.
A novel dual-quenching electrochemiluminescence (ECL) immunosensor based on ECL resonance energy transfer (ECL-RET) strategy was developed for sensitive detection of soluble suppression of tumorigenicity 2 (sST2) protein. The sensor developed a self-accelerated ECL emitter composed of Au-decorated graphitic carbon nitride (g-C₃N₄) nanosheets and Materials of Institute Lavoisier-100(Fe) (MIL-100(Fe)). In this system, the reversible Fe²⁺/Fe³⁺ redox cycling in MIL-100(Fe) markedly enhanced the ECL emission from the g-C₃N₄/S₂O₈²⁻ pair by promoting the generation of sulfate radical. Simultaneously, the incorporated Au nanoparticles facilitated electron transfer and provided abundant sites for biomolecular immobilization, collectively establishing a robust "signal-on" state. Signal quenching was achieved using Pt@CuS nanoflowers as synergistic ECL quenchers. Their high antibody-loading capacity and efficient ECL-RET capability acted in concert to drastically reduce the signal, thereby inducing a pronounced "signal-off" state. The optimized "on-off" ECL immunosensor demonstrated a satisfactory linear range (0.001-100 ng mL⁻¹) and an ultralow detection limit of 0.547 pg mL⁻¹ for sST2. This work established a reliable platform for sST2 quantification, holding substantial potential for advancing heart failure research and clinical early diagnosis.
No takes yet. Share an insight, caveat, or question.
He et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: